Drug Trial Radar · NCT07274085
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
Dec 31, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.
Conditions
- Solid Tumors
Interventions
HDM2017Drug
Participants will be treated with HDM2017 intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP
- Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
- Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.